Power and sample size calculation for incremental net benefit in cost effectiveness analyses with applications to trials conducted by the Canadian Cancer Trials Group

Table 2 Variance of the incremental net benefit estimates by correlation coefficient, assuming a willingness-to-pay threshold of $100,000

Trial	Variance		Relative Changes
Trial	$\boldsymbol\rho\boldsymbol=\mathbf0$	$\boldsymbol\rho\boldsymbol=\boldsymbol o\boldsymbol b\boldsymbol s\boldsymbol e\boldsymbol r\boldsymbol v\boldsymbol e\boldsymbol d$	Relative Changes
BR.10	1,744,993	1,690,399	3%
BR.21	21,792	20,318	7%
LY.12	6,922	6,800	2%
CO.17 (all patients)	8,571	5,477	36%
CO.17 (KRAS subgroup)	22,780	14,610	36%

ISSN: 1471-2288

Trial	Variance		Relative Changes
Trial	\(\boldsymbol\rho\boldsymbol=\mathbf0\)	\(\boldsymbol\rho\boldsymbol=\boldsymbol o\boldsymbol b\boldsymbol s\boldsymbol e\boldsymbol r\boldsymbol v\boldsymbol e\boldsymbol d\)	Relative Changes
BR.10	1,744,993	1,690,399	3%
BR.21	21,792	20,318	7%
LY.12	6,922	6,800	2%
CO.17 (all patients)	8,571	5,477	36%
CO.17 (KRAS subgroup)	22,780	14,610	36%